Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

ctively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communic
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013 Industry leaders from ... for the Oak Ridge National Laboratory’s Biosurveillance ... place at the Hilton Alexandria Mark Center. Held ... 2013 conference on June 18 - 19. ... AdSave, American Elements, Applied Research Associates, ARA, AttaGene, ...
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 iLuv ... line of accessories for the mobile lifestyle, announces they ... sync, protect, and manage multiple iPad devices efficiently. Winner ... and the 2012 Good Design award, MultiCharger-X is revolutionizing ... iPad, wherever it is deployed. , MultiCharger-X ...
(Date:5/22/2013)... Boston, MA (PRWEB) May 22, 2013 ... to present at last week’s “Data Demonstration Day” on Capitol ... Cambridge Semantics joined EMC, Google, Microsoft and others to showcase ... the proposed Digital Accountability and Transparency Act (DATA Act). , ... Darrell Issa (R-CA) and Sen. Mark ...
(Date:5/22/2013)... 22, 2013 The Conference Forum ... Innovations to Advance Clinical Trials conference taking place on ... Boston, MA. , Disruptive thinkers from Novartis, Pfizer, ... share bold approaches to reduce expensive infrastructure, engage patients ... needs to be big, or novel, or it must ...
Breaking Biology Technology:Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 3Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 4Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 5iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2
... DIEGO, Dec. 3, 2010 Sequenom, Inc. (Nasdaq: ... its previously announced common stock offering that priced on ... to purchase an additional 2,100,000 shares of its common ... will total 16,100,000 shares at a public offering price ...
... researchers have discovered a simple way to make ... of researcher Bruce Weisman, a pioneer in nanotube ... to batches of single-walled carbon nanotubes and exposing ... oxygen atoms and systematically changes their near-infrared fluorescence. ...
... 2, 2010 The Board of Directors of the ... investments and customized company formation and business growth services ... approval of the nomination of Peter M. DeComo as ... effective immediately.  Mr. DeComo will replace Dr. D. Lansing ...
Cached Biology Technology:Sequenom Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Sequenom Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Light touch brightens nanotubes 2Light touch brightens nanotubes 3The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board 2
(Date:5/22/2013)... in fuel cell powered buses, including a team ... electrode degradation processes and bus membrane durability. , ... degradation stressors in the operating cycle of the ... of the study, led by SFU graduate student ... study at Burnaby-based Ballard Power Systems and funded ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... join together in a major new effort to educate ... providing Earth,s people with clean water that looms ahead ... comment article in the current edition of Chemical ... American Chemical Society (ACS), the world,s largest scientific society. ... and Jerald L. Schnoor, Ph.D., explain that shortages of ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Detecting mirror molecules 2Detecting mirror molecules 3
... Ariz., Aug. 16, 2011 DAP Technologies, M2000, ... now available with the Microsoft Windows Embedded Handheld ... biometrics module with fingerprint and credential-reading capabilities. ... Windows Embedded Handheld 6.5 is designed specifically for ...
... are found in stem cells could be causing some breast ... recurs. These abnormal cells are likely controlling cell functions in ... and radiation, they enable the disease to recur. The ... physicians at the Oregon Health & Science University Knight Cancer ...
... found in Wisconsin,s deepest and coldest bodies of water, could ... the Wisconsin lakes it now inhabits by the year 2100, ... online in the journal Public Library of Science One ... Department of Natural Resources project a gloomy fate for the ...
Cached Biology News:DAP Technologies Adds Windows Embedded Handheld 6.5 and Biometrics Module to its M2000 Rugged Handheld 2Malignant stem cells may explain why some breast cancers develop and recur 2Climate change could drive native fish out of Wisconsin waters 2
... Dog Serum-Mixed Breed • Dog serum is ... over one year of age Available Anticoagulants: ... Heparin (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
... Purification Kit is designed to purify double-stranded DNA ... synthesis and PCR. The process is simple and ... 3 g can be efficiently purified and concentrated. ... DNA is bound to the Microfilter Cartridge in ...
GOAT ANTI PPP2R5B...
acridine orange 10-nonyl bromide (nonyl acridine orange)...
Biology Products: